Loading...
OTCM
FZMD
Market cap1mUSD
Jul 09, Last price  
0.03USD
1D
32.95%
1Q
70.06%
Jan 2017
-81.72%
Name

Fuse Medical Inc

Chart & Performance

D1W1MN
OTCM:FZMD chart
P/E
15.79
P/S
0.24
EPS
0.00
Div Yield, %
Shrs. gr., 5y
2.09%
Rev. gr., 5y
-15.87%
Revenues
9m
-15.90%
00000001,059,000941,0861,676,60925,667,00026,407,00026,342,00022,900,00021,399,00020,414,00018,645,00016,115,00010,726,0009,020,912
Net income
137k
-73.36%
-88,055-40,844-81,780-110,000-157,000-122,262-102,000-110,000-1,405,000-801,5473,016,000699,6783,958,000-3,316,000-1,432,000-1,588,0003,098,0001,460,000513,960136,912
CFO
173k
P
-56,916-14,087-67,287-100,362-105,067-134,279-53,067-50,883-1,168,784-375,140-237,9061,604,5362,479,900-4,739236,654-1,778,32834,799443,786-148,422172,726
Dividend
Oct 22, 20100.5 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Headquartered in Richardson, Texas, Fuse Medical, Inc. operates as a U.S.-based manufacturer and supplier of medical device implants. Its product portfolio primarily encompasses a wide range of orthopedic implants. This includes specialized internal and external fixation devices for the foot and ankle, as well as plating systems and total joint reconstruction implants designed for upper and lower extremities. Additionally, Fuse Medical provides solutions for soft tissue fixation and augmentation, catering to sports medicine procedures. The company's offerings extend to comprehensive spinal implants, addressing indications such as trauma, degenerative disc disease, and various deformities. Beyond its orthopedic line, the company also supplies osteo-biologics and regenerative products. These encompass a variety of materials such as human allografts, tendons, synthetic skin, bone substitutes, and other regenerative tissues. Fuse Medical's client base includes hospitals, diverse medical facilities, and a network of sub-distributors.
IPO date
Oct 30, 1980
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT